Clinical TrialsSearch results
Number of results: 2568
No Longer Recruiting
- The METABO Trial
- Metabolic syndrome with Dyslipidemia, Diabetes Mellitus, Hypertension and Obesity
- Svensson Kishi Akiko
- 2023-11-19
Recruiting
- "Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Moderate-to-severe AD (ROCKET-SHUTTLE)"
- Atopic Dermatitis
- Schwartz-Sagi Liat
- 2023-04-16
Recruiting
- [M14-682] Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves through the Body of Pediatric and Adolescent Participants with Active Systemic Juvenile Idiopathic Arthritis.
- Juvenile Idiopathic Arthritis
- Hayato Yamazaki
- 2023-10-16
Recruiting
- [M15-340]A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
- Polyarticular Course Juvenile Idiopathic Arthritis
- Yamazaki Hayato
- 2023-01-18
Recruiting
- [M24-122] A Study of Adverse Events, How Intravenously (IV) Infused ABBV-303 Moves Through the Body, and Change in Disease State, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adult Participants With Advanced Solid Tumors
- Solid Tumors
- Yamagishi Chika
- 2024-03-15
Recruiting
- [M24-147] Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
- Hepatocellular Carcinoma
- Yamagishi Chika
- 2023-06-16
Recruiting
- [M24-311]Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
- unresectable metastatic colorectal cancer
- Yamagishi Chika
- 2023-11-10
Recruiting
- [M24-427]ABBV-400 in Select Advanced Solid Tumor Indications
- HCC, PDAC, BTC, ESCC, BC, HNSCC
- Yamagishi Chika
- 2023-12-25
Recruiting
- 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
- Chronic Spontaneous Urticaria
- Maruyama Hideki
- 2024-03-06